Skip to main content
OpenTrials
Completed

NCT Number: NCT04938648

Aligning Medications With What Matters Most

The Aligning Medications with What Matters Most (ALIGN) study will assess the feasibility and preliminary efficacy of a deprescribing intervention to reduce medication regimen complexity and treatment burden for people living with dementia (PLWD) and their care partners.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kaiser Permanente, Aurora, Colorado, United States

Loading trial locations.

About this study

People living with dementia (PLWD) use more medications and have more complex medication regimens than people without dementia. Medication regimen complexity is a major source of burden for family caregivers of PLWD and has been associated with numerous adverse outcomes. Therefore, the investigators propose a novel intervention, ALIGN: Aligning Medications with What Matters Most, to optimize prescribing and reduce medication regimen complexity by focusing on what matters most to the patient and caregiver, beyond rigid adherence to clinical practice guidelines. ALIGN is informed by learnings from OPTIMIZE, the investigator team's patient-centered, pragmatic deprescribing intervention for PLWD in primary care that is currently being prospectively evaluated. OPTIMIZE consists of a patient-level intervention comprised of a deprescribing educational brochure, and a clinician-level intervention comprised of a deprescribing educational session for primary care providers (PCPs), deprescribing "tip sheets" and clinic-level feedback on rates of potentially inappropriate medication prescribing in PLWD. ALIGN builds on OPTIMIZE by more explicitly addressing the informational and decisional needs of caregivers through a shared decision making process facilitated by clinical pharmacists. The investigators propose a pilot study to assess the feasibility and acceptability of ALIGN in two different health care systems, and to identify the most appropriate primary outcome measure for a subsequent embedded pragmatic trial (ePCT). Target enrollment is 60 patient-care partner dyads. Patients will be aged ≥65 years with dementia and >5 chronic medications. Primary outcomes are intervention feasibility and acceptability among patients, care partners and PCPs; and feasibility of the patient-level Medication Regimen Complexity Index and Family Caregiver Medication Administration Hassles Scale at baseline and 3 months. Findings from this pilot study will guide the design, implementation and subsequent evaluation of ALIGN in an ePCT, laying the groundwork to reduce medication regimen complexity and burden for PLWD and their caregivers in diverse primary care settings.

This proposed pragmatic intervention has the following aims:

Specific Aim 1: To assess the feasibility and acceptability of ALIGN in two different health care systems, to guide the subsequent evaluation of the effectiveness of the intervention in an embedded pragmatic trial (ePCT).

Specific Aim 2: To determine the feasibility of the primary and secondary outcome measures for the subsequent ePCT.

  • To determine the feasibility of measuring the primary outcome, the patient-level Medication Regimen Complexity Index (pMRCI), within the existing electronic health record (EHR) systems, and to compare it with a more pragmatic measure, chronic medication count, as the primary outcome measure for the ePCT.
  • To determine the feasibility of measuring the secondary outcome, the Family Caregiver Medication Administration Hassles Scale (FCMAHS), a caregiver-reported outcome measure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 65 or greater
  • Diagnosis of dementia from International Classification of Diseases (ICD) -9 or ICD-10 codes
  • At least one other chronic condition
  • Five or more chronic medications (to include all prescription and over-the-counter medications, both scheduled and as needed)
  • Have a primary care physician at the pilot clinic who has enrolled in the study; this will be defined as having had at least 1 previous visit with that physician

Care partners:

  • Family or other companions age 21 years or greater who regularly help the patient with managing medications

Exclusion criteria

  • As both the pilot and the planned pragmatic trial will be based in primary care, individuals residing in long term care facilities or enrolled in hospice will be excluded.
  • Individuals who cannot converse comfortably in English will be excluded because the FCMAHS has not been validated in other languages.

Treatment and study plan

Pharmacist-led deprescribing intervention

Behavioral
  • direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP

Primary outcomes

  1. Feasibility as Assessed by Proportion of Dyads That Opt Out of the Intervention

    Time frame: A duration of approximately 8 months

    Dyads are comprised of the person living with dementia and their care partner. We will measure the proportion of dyads that opt out of the intervention versus the dyads that agree to participate.

  2. Feasibility as Assessed by the Number of Pharmacist Messages to the Primary Care Provider (PCP) That Receive an Acknowledgment or Response

    Time frame: 3 months after enrollment

    We will measure the number of pharmacist's messages that receive an acknowledgment or response from the PCP based on Electronic Medical Record (EMR) review

  3. Feasibility as Assessed by the Number of Contacts Between Pharmacist and PCP

    Time frame: 3 months after enrollment

    We will measure the number of contacts between pharmacist and PCP based on Electronic Medical Record (EMR) review

  4. Feasibility as Assessed by the Number of Contacts Between Pharmacist and Dyad

    Time frame: 3 months after enrollment

    We will measure the number of contacts between pharmacist and PCP and dyad based on Electronic Medical Record (EMR) review

  5. Feasibility as Assessed by the Direct Time Required by the Pharmacist to Complete the Intervention

    Time frame: 3 months after enrollment

    We will measure the amount of direct time that it takes the pharmacist to complete the intervention. We will access from pharmacist's documentation in the Electronic Medical Record (EMR).

  6. Feasibility as Assessed by the Indirect Time Required by the Pharmacist to Complete the Intervention

    Time frame: 3 months after enrollment

    We will measure the amount of indirect time that it takes the pharmacist to complete the intervention. We will access from pharmacist's documentation in the Electronic Medical Record (EMR).

  7. Feasibility as Assessed by Percentage of Dyads Who Complete 2 of 2 Pharmacist Phone Calls Based on Documented Status Reports

    Time frame: Baseline and 3 months after enrollment

    Dyads are comprised of the person living with dementia and their care partner. We will measure the percentage of dyads who complete 2 of 2 pharmacist phone calls based on documented status reports

  8. Acceptability Will be Assessed by the Acceptance Rates for the Pharmacist's Recommendations

    Time frame: 3 months after enrollment

    We will measure the acceptance rates for the pharmacist's recommendations as documented in the Electronic Medical Record (EMR)

Secondary outcomes

  1. Total Medication Count

    Time frame: Baseline and 3 months after enrollment

    We will measure the total medication count using data obtained from the EHR.

  2. Percentage of Participants With Data Elements Available to Calculate the Medication Regimen Complexity Index (pMRCI)

    Time frame: Baseline and 3 months after enrollment

    The feasibility of measuring this outcome will be determined as follows: Percentage of participants with data elements available vs. unavailable to calculate the pMRCI, within the existing electronic medical record systems.

    This study assessed the feasibility of measuring the pMRCI and not actually determining the pMRCI.

    The pMRCI is a validated, widely-used tool that measures medication regimen complexity to identify patients with expected difficulty managing their regimens. Scores are derived from weighted values of regimen components (eg, dosage formulations, frequencies, and specific instructions for use). Higher scores indicate greater medication regimen complexity.

  3. Medication Regimen Complexity Index (MRCI)

    Time frame: Baseline and 3 months Baseline and 3 months after enrollment

    The MRCI is a validated, widely-used tool that measures medication regimen complexity to identify patients with expected difficulty managing their regimens. The MRCI score is derived from weighted values of regimen components (eg, dosage formulations, frequencies, and specific instructions for use). The score has no upper limit, but higher scores indicate greater medication regimen complexity. Regimen components were combined to compute a total score and averaged.

  4. Response Rate for the Family Caregiver Medication Administration Hassles Scale (FCMAHS)

    Time frame: Baseline and 3 months after enrollment

    We will measure the response rate from care partners to complete the FCMAHS over the phone or electronically.

    The FCMAHS is a validated caregiver-reported outcome measure that assesses burden associated with medication administration. The instrument consists of 24 items and four subscales: Information Seeking/Information Sharing (9 items), Safety Issues (5 items), Scheduling Logistics (7 items) and Polypharmacy (3 items). The total score range is 0-120 with higher scores indicating greater perceived hassle associated with managing some or all aspects of another person's medication regimen.

  5. Time to Complete the Family Caregiver Medication Administration Hassles Scale (FCMAHS)

    Time frame: Baseline and 3 months after enrollment

    We will measure the time it takes the care partner to complete the FCMAHS over the phone or electronically.

    The FCMAHS is a validated caregiver-reported outcome measure that assesses burden associated with medication administration. The instrument consists of 24 items and four subscales: Information Seeking/Information Sharing (9 items), Safety Issues (5 items), Scheduling Logistics (7 items) and Polypharmacy (3 items). The total score range is 0-120 with higher scores indicating greater perceived hassle associated with managing some or all aspects of another person's medication regimen.

  6. Family Caregiver Medication Administration Hassles Scale (FCMAHS)

    Time frame: Baseline and 3 months after enrollment

    The FCMAHS is a validated caregiver-reported outcome measure that assesses burden associated with medication administration. The instrument consists of 24 items and four subscales: Information Seeking/Information Sharing (9 items), Safety Issues (5 items), Scheduling Logistics (7 items) and Polypharmacy (3 items). The total score range is 0-120 with higher scores indicating greater perceived hassle associated with managing some or all aspects of another person's medication regimen.

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Kaiser Permanente
  • National Institute on Aging (NIA)

Registry information

Official study title

Align: Aligning Medications With What Matters Most

Acronym: ALIGN

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jun 24, 2021
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.